Launch
FDA approves cosibelimab-ipdl for metastatic or locally advanced cutaneous squamous cell carcinoma
What's New: Drugs RSS Feed · By FDA ·
The Brief
- On December 13, 2024, the FDA approved cosibelimab-ipdl (Unloxcyt) from Checkpoint Therapeutics.
- The drug is a PD-L1 blocking antibody.
- It is approved for adults with metastatic or locally advanced cutaneous squamous cell carcinoma.
Why it matters
This adds a PD-L1 blocking antibody option for adults with advanced cutaneous squamous cell carcinoma, a skin cancer that can spread beyond its original site.
Who’s affected
- Adults with metastatic cutaneous squamous cell carcinoma
- Adults with locally advanced cutaneous squamous cell carcinoma
- #fda
- #oncology
- #immunotherapy
- #cutaneous-squamous-cell-carcinoma
- #pd-l1
- #drug-approval
On December 13, 2024, the FDA approved cosibelimab-ipdl (Unloxcyt, Checkpoint Therapeutics, Inc.), a programmed death ligand-1 (PD-L1) blocking antibody, for adults with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC).
Timeline
FDA approves cosibelimab-ipdl (Unloxcyt) for metastatic or locally advanced cutaneous squamous cell carcinoma
What's New: Drugs RSS Feed
FDA approves cosibelimab-ipdl for metastatic or locally advanced cutaneous squamous cell carcinoma